Patents by Inventor Samantha J. Busfield
Samantha J. Busfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230416356Abstract: The present disclosure relates to an antigen-binding molecule that specifically binds to interleukin-31 (IL-31), wherein the antigen-binding molecule comprises an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain.Type: ApplicationFiled: November 22, 2021Publication date: December 28, 2023Inventors: Samantha J. BUSFIELD, Matthew J. WILSON
-
Publication number: 20230391862Abstract: Provided are methods for suppressing an immune response to a therapeutic protein encoded by a vector in a subject in need thereof and associated compositions. The method may include selecting a subject as the subject in need of treatment with the vector and then administering to the subject a composition comprising the therapeutic protein or a homolog or functional variant thereof, optionally an immunologically related variant thereof.Type: ApplicationFiled: October 20, 2021Publication date: December 7, 2023Inventors: Samantha J. BUSFIELD, Matthew J. WILSON
-
Publication number: 20230365670Abstract: The present disclosure relates to an antigen-binding molecule that specifically binds to nerve growth factor (NGF) and uses thereof.Type: ApplicationFiled: June 21, 2023Publication date: November 16, 2023Inventors: Samantha J. BUSFIELD, Matthew J. WILSON
-
Patent number: 8137923Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: January 20, 2010Date of Patent: March 20, 2012Assignee: Millennium Pharmaceuticals, Inc.Inventors: Samantha J. Busfield, Jean-Luc Villeval
-
Publication number: 20110020798Abstract: Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST proteins, the invention further provides isolated ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST fusion proteins, antigenic peptides and anti-ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST antibodies. The invention also provides ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: December 18, 2009Publication date: January 27, 2011Inventors: Douglas A. Holtzman, Sean A. McCarthy, Kyle J. MacBeth, Samantha J. Busfield, Yang Pan, David White, Mehran M. Khodadoust, Wei Gu
-
Publication number: 20100279313Abstract: The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.Type: ApplicationFiled: June 30, 2008Publication date: November 4, 2010Inventor: Samantha J. Busfield
-
Publication number: 20100261200Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: January 20, 2010Publication date: October 14, 2010Inventors: Samantha J. Busfield, Jean-Luc Villeval, Martine Jandrot-Perrus, William Vainchencker
-
Patent number: 7803564Abstract: The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1,2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-?. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: GrantFiled: September 26, 2007Date of Patent: September 28, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Samantha J. Busfield, David P. Gearing
-
Publication number: 20090286956Abstract: The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted.Type: ApplicationFiled: October 12, 2007Publication date: November 19, 2009Inventors: Sean A. McCarthy, David P. Gearing, Douglas A. Holtzman, Yang Pan, Samantha J. Busfield, Thomas M. Barnes, Charles R. Mackay, Jose M. Lora
-
Publication number: 20090117583Abstract: The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1,2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-?. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: ApplicationFiled: September 26, 2007Publication date: May 7, 2009Inventors: Samantha J. Busfield, David P. Gearing
-
Publication number: 20080248477Abstract: Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST proteins, the invention further provides isolated ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST fusion proteins, antigenic peptides and anti-ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST antibodies. The invention also provides ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: December 11, 2007Publication date: October 9, 2008Inventors: Douglas A. Holtzman, Sean A. McCarthy, Kyle J. MacBeth, Samantha J. Busfield, Yang Pan, David White, Mehran M. Khodadoust, Wei Gu
-
Publication number: 20080220495Abstract: The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted.Type: ApplicationFiled: October 12, 2007Publication date: September 11, 2008Inventors: Sean A. McCarthy, David P. Gearing, Douglas A. Holtzman, Yang Pan, Samantha J. Busfield, Thomas M. Barnes, Charles R. Mackay, Jose M. Lora
-
Patent number: 7408038Abstract: The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.Type: GrantFiled: December 20, 2006Date of Patent: August 5, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventor: Samantha J. Busfield
-
Patent number: 7294482Abstract: The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1, 2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-?. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The ELVIS nucleic acids of the present invention are useful as modulating agents in regulating a variety of cellular processes, and are particularly useful for diagnostic, screening and therapeutic methods for the treatment of skin conditions, such as for wound healing.Type: GrantFiled: January 16, 2003Date of Patent: November 13, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Samantha J. Busfield, David P. Gearing
-
Patent number: 7291714Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: February 14, 2000Date of Patent: November 6, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Samantha J. Busfield, Jean-Luc Villeval
-
Patent number: 7202029Abstract: The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.Type: GrantFiled: September 25, 2002Date of Patent: April 10, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventor: Samantha J. Busfield
-
Patent number: 6852837Abstract: Novel TANGO-69-receptor polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length TANGO-69-receptor proteins, the invention further provides isolated TANGO-69-receptor fusion proteins, antigenic peptides and anti-TANGO-69-receptor antibodies. The invention also provides TANGO-69-receptor nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a TANGO-69-receptor gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: August 21, 2001Date of Patent: February 8, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventor: Samantha J. Busfield
-
Publication number: 20040265970Abstract: The present invention relates to the identification and characterization of a novel gene called don-1 related to epidermal growth factors (EGF) such as the neuregulins, and methods of preparing and using alternate splice forms of this gene to express new Don-1 polypeptides.Type: ApplicationFiled: July 26, 2004Publication date: December 30, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: David P. Gearing, Samantha J. Busfield
-
Publication number: 20040176296Abstract: Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST proteins, the invention further provides isolated ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST fusion proteins, antigenic peptides and anti-ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST antibodies. The invention also provides ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: March 22, 2004Publication date: September 9, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Douglas A. Holtzman, Sean A. McCarthy, Kyle J. MacBeth, Samantha J. Busfield, Yang Pan, David White, Mehran M. Khodadoust, Wei Gu
-
Publication number: 20030138912Abstract: The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1, 2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-A. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The ELVIS nucleic acids of the present invention are useful as modulating agents in regulating a variety of cellular processes, and are particularly useful for diagnostic, screening and therapeutic methods for the treatment of skin conditions, such as for wound healing.Type: ApplicationFiled: January 16, 2003Publication date: July 24, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Samantha J. Busfield, David P. Gearing